

Rizatriptan Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 4.0 | 06.04.2024 | 402599-00019 | Date of first issue: 10.12.2015 |

Section 1: Identification

Product identifier : Rizatriptan Formulation

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical
Restrictions on use : Not applicable


Manufacturer or supplier's details

Company : Organon & Co.
Address : 30 Hudson Street, 33rd floor
Jersey City, New Jersey, U.S.A 07302
Telephone : +1-551-430-6000
Emergency telephone number : +1-215-631-6999
E-mail address : EHSSTEWARD@organon.com

Section 2: Hazard identification**Classification of the substance or mixture**

Reproductive toxicity : Category 2
Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Cardio-vascular system)

GHS Label elements, including precautionary statements

Hazard pictograms : 

Signal word : Warning

Hazard statements : H361d Suspected of damaging the unborn child.
H373 May cause damage to organs (Cardio-vascular system) through prolonged or repeated exposure if swallowed.

Precautionary statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P280 Wear protective gloves/ protective clothing/ eye protec-

Rizatriptan Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 4.0 | 06.04.2024 | 402599-00019 | Date of first issue: 10.12.2015 |

tion/ face protection/ hearing protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

| Chemical name | CAS-No. | Concentration (% w/w) |
|---------------|-------------|-----------------------|
| Cellulose | 9004-34-6 | >= 50 -< 70 |
| Starch | 9005-25-8 | >= 10 -< 20 |
| Rizatriptan | 145202-66-0 | >= 3 -< 10 |

Section 4: First-aid measures**Description of necessary first-aid measures**

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed

- Risks : Suspected of damaging the unborn child.

Rizatriptan Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: |
| 4.0 | 06.04.2024 | 402599-00019 | 04.04.2023 |
| | | | Date of first issue: 10.12.2015 |

May cause damage to organs through prolonged or repeated exposure if swallowed.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

Section 5: Fire-fighting measures**Extinguishing media**

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Special protective actions for fire-fighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Section 6: Accidental release measures**Personal precautions, protective equipment and emergency procedures**

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.

Rizatriptan Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 4.0 | 06.04.2024 | 402599-00019 | Date of first issue: 10.12.2015 |

Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
 Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
 Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
 Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
 Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage**Precautions for safe handling**

| | | |
|-------------------------|---|---|
| Technical measures | : | Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | : | Use only with adequate ventilation. |
| Advice on safe handling | : | Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

Rizatriptan Formulation

Version 4.0 Revision Date: 06.04.2024 SDS Number: 402599-00019 Date of last issue: 04.04.2023
 Date of first issue: 10.12.2015

Conditions for safe storage, including any incompatibilities

Conditions for safe storage : Keep in properly labelled containers.
 Store locked up.
 Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
 Strong oxidizing agents

Section 8: Exposure controls/personal protection**Control parameters****Occupational Exposure Limits**

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis |
|-------------|-------------|----------------------------------|--|----------|
| Cellulose | 9004-34-6 | PEL (long term) | 10 mg/m ³ | SG OEL |
| | | TWA | 10 mg/m ³ | ACGIH |
| Starch | 9005-25-8 | PEL (long term) | 10 mg/m ³ | SG OEL |
| | | TWA | 10 mg/m ³ | ACGIH |
| Rizatriptan | 145202-66-0 | TWA | 10 µg/m ³ (OEB 3) | Internal |
| | | Wipe limit | 100 µg/100 cm ² | Internal |

Appropriate engineering control measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
 Minimize open handling.

Individual protection measures, such as personal protective equipment (PPE)

Eye/face protection : Wear safety glasses with side shields or goggles.
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin protection : Work uniform or laboratory coat.
 Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
 Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

SAFETY DATA SHEET



Rizatriptan Formulation



Version 4.0 Revision Date: 06.04.2024 SDS Number: 402599-00019 Date of last issue: 04.04.2023
Date of first issue: 10.12.2015

Filter type : Particulates type
Hand protection
Material : Chemical-resistant gloves
Remarks : Consider double gloving.

Section 9: Physical and chemical properties

Appearance : powder
Colour : pink
Odour : odourless
Odour Threshold : No data available
pH : No data available
Melting point/freezing point : No data available
Initial boiling point and boiling range : No data available
Flash point : Not applicable
Evaporation rate : No data available
Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids) : No data available
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapour pressure : No data available
Relative vapour density : No data available
Density : No data available
Solubility(ies)
Water solubility : No data available
Partition coefficient: n-octanol/water : No data available
Auto-ignition temperature : No data available
Decomposition temperature : No data available

Rizatriptan Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 4.0 | 06.04.2024 | 402599-00019 | Date of first issue: 10.12.2015 |

Viscosity
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics
Particle size : No data available

Section 10: Stability and reactivity

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

Section 11: Toxicological information

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:**Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Rizatriptan Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 4.0 | 06.04.2024 | 402599-00019 | Date of first issue: 10.12.2015 |

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Rizatriptan:

Acute oral toxicity : LD50 (Rat): 2,227 mg/kg

LD50 (Mouse): 700 - 1,631 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:**Rizatriptan:**

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Starch:**

Species : Rabbit

Result : No eye irritation

Rizatriptan:

Species : Bovine cornea

Remarks : Moderate eye irritation

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Starch:**

Test Type : Maximisation Test

Exposure routes : Skin contact

Species : Guinea pig

Result : negative

Rizatriptan Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 4.0 | 06.04.2024 | 402599-00019 | Date of first issue: 10.12.2015 |

Rizatriptan:

| | |
|-----------------|--------------------------------------|
| Test Type | : Maximisation Test |
| Exposure routes | : Dermal |
| Species | : Guinea pig |
| Assessment | : Does not cause skin sensitisation. |
| Result | : negative |

Germ cell mutagenicity

Not classified based on available information.

Components:**Cellulose:**

| | |
|-----------------------|--|
| Genotoxicity in vitro | : Test Type: Bacterial reverse mutation assay (AMES) |
| | Result: negative |
| Genotoxicity in vivo | : Test Type: In vitro mammalian cell gene mutation test |
| | Result: negative |
| Genotoxicity in vivo | : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) |
| | Species: Mouse |
| | Application Route: Ingestion |
| | Result: negative |

Starch:

| | |
|-----------------------|--|
| Genotoxicity in vitro | : Test Type: Bacterial reverse mutation assay (AMES) |
| | Result: negative |

Rizatriptan:

| | |
|-----------------------|--|
| Genotoxicity in vitro | : Test Type: Bacterial reverse mutation assay (AMES) |
| | Result: negative |
| | Test Type: Alkaline elution assay |
| | Result: negative |
| Genotoxicity in vivo | : Test Type: In vitro mammalian cell gene mutation test |
| | Result: negative |
| | Test Type: Chromosome aberration test in vitro |
| | Result: negative |
| Genotoxicity in vivo | : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) |
| | Species: Mouse |
| | Application Route: Oral |
| | Result: negative |

Carcinogenicity

Not classified based on available information.

Rizatriptan Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 4.0 | 06.04.2024 | 402599-00019 | Date of first issue: 10.12.2015 |

Components:**Cellulose:**

| | |
|-------------------|-------------|
| Species | : Rat |
| Application Route | : Ingestion |
| Exposure time | : 72 weeks |
| Result | : negative |

Rizatriptan:

| | |
|-------------------|-------------------------|
| Species | : Mouse |
| Application Route | : Oral |
| Exposure time | : 100 weeks |
| NOAEL | : 125 mg/kg body weight |
| Result | : negative |

| | |
|-------------------|-------------------------|
| Species | : Rat |
| Application Route | : Oral |
| Exposure time | : 106 weeks |
| NOAEL | : 106 mg/kg body weight |
| Result | : negative |

Reproductive toxicity

Suspected of damaging the unborn child.

Components:**Cellulose:**

| | |
|----------------------|---|
| Effects on fertility | : Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative |
|----------------------|---|

| | |
|-------------------------------|--|
| Effects on foetal development | : Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Result: negative |
|-------------------------------|--|

Rizatriptan:

| | |
|----------------------|---|
| Effects on fertility | : Test Type: Fertility/early embryonic development Species: Rat, female Application Route: Oral Fertility: LOAEL: 100 mg/kg body weight Symptoms: altered estrus cycles Result: No effects on fertility and early embryonic development were detected. |
|----------------------|---|

| | |
|--|--|
| | : Test Type: Fertility/early embryonic development Species: Rat, male Application Route: Oral Fertility: NOAEL: 250 mg/kg body weight Result: No effects on fertility and early embryonic development were detected. |
|--|--|

Rizatriptan Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 4.0 | 06.04.2024 | 402599-00019 | Date of first issue: 10.12.2015 |

| | | |
|------------------------------------|---|--|
| | | ment were detected. |
| Effects on foetal development | : | Test Type: Embryo-foetal development Species: Rat Application Route: Oral Developmental Toxicity: LOAEL: 10 mg/kg body weight Result: No teratogenic effects, Embryo-foetal toxicity Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral Developmental Toxicity: LOAEL: 100 mg/kg body weight Result: No teratogenic effects, Embryo-foetal toxicity Remarks: The effects were seen only at maternally toxic doses. |
| Reproductive toxicity - Assessment | : | Some evidence of adverse effects on development, based on animal experiments. |

STOT - single exposure

Not classified based on available information.

Components:**Rizatriptan:**

| | | |
|------------|---|------------------------------------|
| Assessment | : | May cause drowsiness or dizziness. |
|------------|---|------------------------------------|

STOT - repeated exposure

May cause damage to organs (Cardio-vascular system) through prolonged or repeated exposure if swallowed.

Components:**Rizatriptan:**

| | | |
|---------------|---|---|
| Target Organs | : | Cardio-vascular system |
| Assessment | : | Causes damage to organs through prolonged or repeated exposure. |

Repeated dose toxicity**Components:****Cellulose:**

| | | |
|-------------------|---|----------------|
| Species | : | Rat |
| NOAEL | : | >= 9,000 mg/kg |
| Application Route | : | Ingestion |
| Exposure time | : | 90 Days |

Starch:

| | | |
|---------|---|----------------|
| Species | : | Rat |
| NOAEL | : | >= 2,000 mg/kg |

Rizatriptan Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 4.0 | 06.04.2024 | 402599-00019 | Date of first issue: 10.12.2015 |

| | |
|-------------------|---------------------------|
| Application Route | : Skin contact |
| Exposure time | : 28 Days |
| Method | : OECD Test Guideline 410 |

Rizatriptan:

| | |
|-------------------|--|
| Species | : Rat |
| LOAEL | : 1 mg/kg |
| Application Route | : Oral |
| Exposure time | : 14 Weeks |
| Symptoms | : Dilatation of the pupil, Increased pulse rate, Redness |

| | |
|-------------------|--|
| Species | : Dog |
| LOAEL | : 0.05 mg/kg |
| Application Route | : Intravenous |
| Exposure time | : 2 Weeks |
| Symptoms | : Dilatation of the pupil, Increased pulse rate, Redness |

| | |
|-------------------|---------------------------|
| Species | : Dog |
| LOAEL | : 0.2 mg/kg |
| Application Route | : Oral |
| Exposure time | : 1 yr |
| Symptoms | : Dilatation of the pupil |

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Rizatriptan:**

| | |
|-----------|---|
| Ingestion | : Target Organs: Cardio-vascular system Symptoms: asthenia, Fatigue, Pain, Dizziness, Weakness, Drowsiness |
|-----------|---|

Section 12: Ecological information**Toxicity****Components:****Cellulose:**

| | |
|------------------|--|
| Toxicity to fish | : LC50 (<i>Oryzias latipes</i> (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials |
|------------------|--|

Rizatriptan:

| | |
|-------------------------------|--|
| Toxicity to fish | : LC50 (<i>Pimephales promelas</i> (fathead minnow)): > 1,000 mg/l Exposure time: 96 h |
| Toxicity to daphnia and other | : EC50 (<i>Daphnia magna</i> (Water flea)): 1,000 mg/l |

Rizatriptan Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 4.0 | 06.04.2024 | 402599-00019 | Date of first issue: 10.12.2015 |

| | |
|--|---|
| aquatic invertebrates | Exposure time: 48 h |
| Toxicity to algae/aquatic plants | : EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 48 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 |
| Toxicity to fish (Chronic toxicity) | : NOEC (Pimephales promelas (fathead minnow)): 9.6 mg/l Exposure time: 32 d Method: OECD Test Guideline 210 |
| Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) | : NOEC (Daphnia magna (Water flea)): 110 mg/l Exposure time: 21 d Method: OECD Test Guideline 211 |
| Toxicity to microorganisms | : EC50: > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 NOEC: 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 |

Persistence and degradability**Components:****Cellulose:**

| | |
|------------------|----------------------------------|
| Biodegradability | : Result: Readily biodegradable. |
|------------------|----------------------------------|

Rizatriptan:

| | |
|------------------|--|
| Biodegradability | : Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 13 d Method: OECD Test Guideline 314 |
|------------------|--|

Bioaccumulative potential**Components:****Rizatriptan:**

| | |
|--|-------------------|
| Partition coefficient: n-octanol/water | : log Pow: -0.649 |
|--|-------------------|

Rizatriptan Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 4.0 | 06.04.2024 | 402599-00019 | Date of first issue: 10.12.2015 |

Mobility in soil**Components:****Rizatriptan:**

| | | |
|---|---|--|
| Distribution among environmental compartments | : | log Koc: 3.83 Method: OECD Test Guideline 106 |
|---|---|--|

Other adverse effects

No data available

Section 13: Disposal considerations**Disposal methods**

| | | |
|------------------------|---|---|
| Waste from residues | : | Do not dispose of waste into sewer. Dispose of in accordance with local regulations. |
| Contaminated packaging | : | Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product. |

Section 14: Transport information**International Regulations****UNRTDG**

| | | |
|----------------------------|---|----------------|
| UN number | : | Not applicable |
| UN proper shipping name | : | Not applicable |
| Transport hazard class(es) | : | Not applicable |
| Subsidiary risk | : | Not applicable |
| Packing group | : | Not applicable |
| Labels | : | Not applicable |
| Environmentally hazardous | : | no |

IATA-DGR

| | | |
|--|---|----------------|
| UN/ID No. | : | Not applicable |
| UN proper shipping name | : | Not applicable |
| Class | : | Not applicable |
| Subsidiary risk | : | Not applicable |
| Packing group | : | Not applicable |
| Labels | : | Not applicable |
| Packing instruction (cargo aircraft) | : | Not applicable |
| Packing instruction (passenger aircraft) | : | Not applicable |

IMDG-Code

| | | |
|-------------------------|---|----------------|
| UN number | : | Not applicable |
| UN proper shipping name | : | Not applicable |
| Class | : | Not applicable |
| Subsidiary risk | : | Not applicable |
| Packing group | : | Not applicable |
| Labels | : | Not applicable |

SAFETY DATA SHEET



Rizatriptan Formulation



| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 4.0 | 06.04.2024 | 402599-00019 | Date of first issue: 10.12.2015 |

EmS Code : Not applicable
Marine pollutant : Not applicable

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

Not applicable

Section 15: Regulatory information

Safety, health and environmental regulations specific for the product in question

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

Environmental Protection and Management Act and : Not applicable
Environmental Protection and Management (Hazardous Substances) Regulations

Fire Safety (Petroleum and Flammable Materials) : Not applicable
Regulations

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

Section 16: Other information

Revision Date : 06.04.2024

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
SG OEL : Singapore. Workplace Safety and Health (General Provisions) Regulations - First Schedule Permissible Exposure Limits of Toxic Substances.

ACGIH / TWA : 8-hour, time-weighted average

SAFETY DATA SHEET



Rizatriptan Formulation



| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
| 4.0 | 06.04.2024 | 402599-00019 | Date of first issue: 10.12.2015 |

SG OEL / PEL (long term) : Permissible Exposure Level (PEL) Long Term

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN